DOCSLIB.ORG

UIT CAMBRIDGE Rights Catalogue the Physics of Everyday Life Extraordinary Insights Into Everyday Physics Professor Jo Hermans

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
UIT CAMBRIDGE Rights Catalogue the Physics of Everyday Life Extraordinary Insights Into Everyday Physics Professor Jo Hermans UIT CAMBRIDGE rights catalogue The Physics of Everyday Life Extraordinary insights into everyday physics Professor Jo Hermans Description: This book brings the magic of physics to everyday life. With a glass of water, a few drops of milk and a torch, readers will be able to demonstrate why the sky looks blue during the day, but seems to turn red at sunset – and astound their friends by telling them how fast one can cycle on the moon. It will appeal to teenagers and their parents alike. 198 mm x 129 mm, 1 September 2018, Paperback The Author Prof. Jo Hermans is Emeritus Professor of Physics at Leiden University in the Key Selling Points: Netherlands. In addition to his academic research and teaching career he is active in • A best-seller in the Netherlands promoting and explaining science for the general public. He writes a books on everyday where it was originally published science which have been translated worldwide. He was appointed Knight in the Order of • A popular science book focusing Oranje-Nassau by Queen Beatrix in 2010. on the physics ruling everyday phenomena Contents: • Full of theoretical explanations OUTDOOR LIFE 8. Why is the sky blue (and the setting sun red)? and practical experiments 1. GPS navigation, how does it work? (With a tip SOUND AND HEARING of the hat to Einstein) 9. What do our ears hear? BICYCLE AND CAR 10. Why is there not more noise pollution? 2. The human engine when idling IN AND AROUND THE HOUSE 3. Me? A vacuum cleaner? 11. The lid on the pan 4. How do I keep my temperature constant? 12. Why does an egg explode in the microwave? LIGHT AND COLOR 13. Can I cool my home using the refrigerator? 5. Candlelight is cozy 6. Why is an incandescent bulb so inefficient? 7. Fluorescent lights and LEDs: luminous ideas Rights Sold: • Dutch 2 UIT CAMBRIDGE Brain and Mind: Without the Hot Air Professor David Nutt Description: Most scientists agree that the two last – and arguably greatest – challenges to human comprehension are the origins of the universe and the workings of the human brain. This book is about the nature of the human brain and how modern neuroscience and the study of drugs that alter consciousness have given us new and important insights into how it works. Find out how the brain is constructed and how the different parts work and understand the role of the neurotransmitters that neurons use to communicate with each other. Explore the nature of different states of consciousness such as sleep, coma and mental illnesses. Learn about what makes our brains truly human. Key Selling Points: • A new installment of the best- 198 mm x 129 mm, September 2019, Paperback selling Without the Hot Air series • Learn about the human brain from an expert The Author neurolopsychopharmacologist David Nutt is Edmond J Safra Professor of Neurosychopharmacology at Imperial • Prof David Nutt is a prominent College, London. He was Chair of the ACMD’s Technical Committee for seven years, media figure, his recent and became chairman of the Independent Scientific Committee on Drugs in 2010. He appearances include The Times, is the inventor of alcosynth - a substance that mimics the pleasant effects of alcohol Financial Times, The Economist, without causing a hangover. Elle, Daily Star, Daily Mail, The Daily Telegraph, Evening Standard, Huffington Post, BBC Radio , I Fucking Love Science • Professor David Nutt’s previous Contents: title, Drugs Without the Hot Air Part I How the brain works 11. Thinking feeling and consciousness sold 17, 5000 copies 1. The origins of our brains – ions, 12. The emotional brain membranes and pumps 13. Getting inside the head – from brain 2. Neurotransmitters and their receptors – surgery to new imaging techniques the locks and keys of brain function Part II The mind and altered states of 3. Sense about serotonin consciousness Rights Sold: 4. Noradrenaline – fight and flight 14. In-extremis: near death experiences 5. Dopamine – the get up and go and vegetative states • None neurotransmitter 15. Affliction of the gods – Epilepsy 6. Endorphins – from pain to pleasure 16. The devil in depression 7. The tower of complexity – the structure 17. Schizophrenia and mania of the brain 18. Obsessive compulsions and behaviours 8. The vital role of subconscious 19. Addiction – from pleasure to pain processing 20. Conclusions and perspectives 9. How the cortex works 10. Taking control - from urges to self discipline UIT CAMBRIDGE 3 The Brain Mark Millan Description: There are many books about the brain – but not that many that are humorous and pitched at a general audience. Mark Millan’s upbeat book spares you the trouble of wading through more comprehensive tomes by condensing much of the latest scientific knowledge about the brain into an easily-digestible, explanatory and entertaining read. 198 mm x 129 mm, 1 September 2019, Paperback The Author Mark J. Millan was born in Edinburgh, Scotland. He possesses B.A., M.A. and Ph.D. degrees in Natural Sciences from the University of Cambridge, UK, and spent nearly Key Selling Points: 10 years at the Max-Planck Institute for Psychiatry in Munich, where he was awarded • A humurous introduction to the the Serturner Prize for his work on pain, mood and endogenous opioids. brain by a working neuroscientist • The book covers both animal and human brains • Appeals both to aspiring Contents: biologists and neuroscientists and 1.What is a brain ? Variations on a 6. The troubled brain : what to do about a general audience common theme it 2.The human brain in close-up : core 7. Amazing brains design and basic functions 8.Famous brains 3.Genesis of the human brain :why so 9. New generation brains : the rise and big, why so complex ? rise of artificial intelligence 4.Thinking about the brain : a cerebral history tour 5.Studying the brain : who does what ? Rights Sold: • None 4 UIT CAMBRIDGE Solar Energy The physics and engineering of photovoltaic conversion technologies and systems Arnohm Smets, Klaus Jäger, Olindo Isabella, René van Swaaij and Miro Zeman Description: This book uniquely covers both the physics of photovoltaic (PV) cells and the design of PV systems for real-life applications. It includes: • Fundamental principles of semiconductor solar cells. • PV technology: crystalline silicon solar cells; thin-film cells; PV modules; third- generation concepts. • PV systems, from simple stand-alone, to complex systems connected to the grid; components; design; deployment; performance. Key Selling Points: • Over 25,000 free e-books sold, The book is an invaluable reference for researchers, industrial engineers and designers 1752 copies of the physical book working in solar energy generation. The book is also ideal for university and third-level • Ideal for people who are taking physics or engineering courses on solar photovoltaics, with exercises to heck students’ part in online courses as well as understanding and reinforce learning. It is the perfect companion to the Massive Open traditional study. Online Course (MOOC) on Solar Energy (DelftX, ET.3034TU) presented by co-author • Tied to Massive Open Online Arno Smets. The course is available in English on the nonprofit open source edX.org Course with over 100,000 platform, and in Arabic on edraak.org. Over 100,000 students have already registered for registrations. these MOOCs. 496 pages, 241mm x 184mm, 2016, Paperback The Author The authors all teach and research physics at the University of Delft in the Netherlands. They are prominent in the field of solar photovoltaics and are passionate about the development of sustainable energy systems for a greener future. Rights Sold: • Dutch • German Contents: • PV Fundamentals • PV Technology • PV Systems • Alternative solar energy conversion technologies • Appendix UIT CAMBRIDGE 5 Drugs: Without the Hot Air Minimising the harms of legal and illegal drugs Professor David Nutt Description: The science of what drugs are and how they work lets us quantify and compare the harms caused by different drugs. With this information we can radically transform drugs law, and hugely reduce crime and other social, economic and health harms currently caused by drugs. The book is written with a trade audience in mind. • It explains what drugs are, how they work, and how people become addicted. • How harmful are alcohol and tobacco compared to illegal drugs? • Does the ‘War on Drugs’ cause more harm than good? How does it affect legitimate scientific research into potentially valuable therapies? • What should you tell your children about drugs, and at what age? Key Selling Points: 356 pages, 198 mm x 129 mm, 1 September 2019, Paperback • 17,500 copies of the previous edition sold • Prof David Nutt is a prominent The Author media figure, his recent David Nutt is Edmond J Safra Professor of Neurosychopharmacology at Imperial appearances include The Times, College, London. He was Chair of the ACMD’s Technical Committee for seven years, Financial Times, The Economist, and became chairman of the Independent Scientific Committee on Drugs in 2010. He Elle, Daily Star, Daily Mail, is the inventor of alcosynth - a substance that mimics the pleasant effects of alcohol The Daily Telegraph, Evening without causing a hangover. Standard, Huffington Post, BBC Radio , I Fucking Love Science International publicity for Professor David Nutt: • Author has appeared on Channel 4’s Drugs Live: Cannabis “Er hat Drugscience zu einer globalen Institution programme ausgebaut, führt seine Psilocybin-Forschung weiter und hat • Author appears at multiple events im Frühjahr 2016 die weltweit ersten bildgebenden Verfahren and conferences around the world mit Gehirnen unter LSD-Einfluss durchgeführt.” and is actively engaged in social Brand Eins Magazine media “Le principal conseiller du gouvernement britannique sur les drogues estime que l’ecstasy, le cannabis ou le LSD sont des substances moins dangereuses que l’alcool ou la cigarette, dans un rapport universitaire controversé publié Rights Sold: aujourd’hui.” • None Le Figaro “Naukowcy pod wodzą profesora Davida Nutta opracowali recepturę napoju, który jak twierdzą, potrafi doprowadzić do stanu nietrzeźwości.
Load more

Recommended publications
  • Neurobiology of Addiction and Implications for Treatment
    BRITISH JOURNAL OF PSYCHIATRY (2003), 182, 97^100 EDITORIAL partial agonist, this drug stimulates the D Neurobiology of addiction and implications 33 receptor enough to keep withdrawal at for treatment bay, but not enough to cause a ‘high’ or to be rewarding. It is currently in phase 1 trials. One drug that affects the dopaminergic ANNE LINGFORD-HUGHES and DAVID NUTT system and has proven efficacy in the treat- ment of nicotine addiction is bupropion (Jorenby(Jorenby et aletal, 1999). The exact mechanism underlying this effect still has to be fully characterised; however, it has been shown that bupropion increases dopamine and noradrenaline levels by acting as an uptake Drug and alcohol misuse result in immense withdrawal as well. In an elegant series of inhibitor (Ascher et aletal, 1995).,1995). harm at both individual and societal level. experiments, Schultz (2001) found that in Our understanding of the neuropharma- primates trained to associate a cue with a cology of these disorders is increasing pleasurable experience (food), increased Related systems involved in reward through the use of approaches such as dopaminergic activity was seen in response Our understanding of other neurotrans- neuroimaging and gene targeting and the to the cue and not to the food. If the food mitter systems that are involved in reward availability of specific receptor agonists was not then presented, dopaminergic and that may modulate dopaminergic and antagonists. Our aim here is to describe function dropped. Reduced dopaminergic activity provides further targets for some interesting new findings that are function is thought to be associated with pharmacotherapy. likely to inform advances in treatment.
    [Show full text]
  • Professor David J Nutt
    2016 BAP LIFETIME ACHIEVEMENT AWARD Professor David J Nutt David Nutt received the BAP Lifetime Achievement Award at the 2016 summer meeting in Brighton. It gives me much pleasure to write about his long and very productive career in both preclinical and clinical psychopharmacology. I am primarily emphasizing his scientific achievements, both internationally and domestic, and his role in making the public aware of the need for evidence-based clinical science. It is scarcely necessary to detail his commitment to the BAP both as a former President and also editor of the Journal of Psychopharmacology for over 25 years. I have known David for nearly 35 years ever since he joined the MRC Clinical Pharmacology Unit in Oxford and undertook preclinical research for his MD. His enormous enthusiasm for both basic and clinical pharmacology and his impressive abilities were apparent from the outset, and in just 3 years we published together 11 papers and a book chapter, all in major journals (he also published work with other colleagues). A particular interest of David was the translation of basic research to clinical studies in psychiatry, something both David Grahame-Smith, the Unit Director, and I were already enthusiastic about. He then undertook clinical research in psychiatry in Oxford before appointments at the National Institutes of Health, Bethesda, Maryland, the University of Bristol and now Imperial College, London. David’s commitment to communicating clinical pharmacology research to the public is, of course, known to many people, and he has been tireless in demonstrating the need for evidence-based decision making when discussing the risks and benefits of drugs, particularly recreational drugs.
    [Show full text]
  • Nutt Dismissal in Britain Highlights Diverging Drug Views
    NEWS Testy debate: Looking ahead: 2009 in review: Biomarkers for Warwick Anderson We take a look prostate cancer discusses funding back at the past stir controversy in Australia year’s headlines 1339 1346 1348 Nutt dismissal in Britain highlights diverging drug views At a time when the US government has Jacqui Smith over a paper Nutt published in signaled a softer stance on medical marijuana, January on perceptions of risk that compared the dismissal of an independent drug advisor 3,4-methylenedioxymethamphetamine in Britain has highlighted the UK’s hard-line (MDMA, or ‘ecstasy’) use to horse riding (J. stance on illegal substances. Psychopharmacol. 23, 3–5; 2009). David Nutt, until recently chair of the Advisory Council on the Misuse of Drugs Public dispute (ACMD), was fired by UK Home Secretary In a statement, Johnson claimed that Nutt’s Alan Johnson on 30 October. The sacking comments “damage efforts to give the public followed the issuing of a press release relating clear messages about the dangers of drugs.” to a lecture on drug risk and classification that Nutt, however, has hit back in a series of Nutt gave in July at King’s College London. interviews attacking the Labour government’s In his lecture, Nutt criticized the lack of approach to the issue of drugs. evidence for the current classification of drugs As Nature Medicine went to press, no less in the UK and claimed that this undermined than five members of the ACMD had resigned the credibility of the official message on drugs. in protest of Nutt’s dismissal.
    [Show full text]
  • 10 Facts About MDMA
    10 Facts About MDMA August 2015 1. What is MDMA? and a desire to intensify these feelings by dancing, talking and touching. MDMA, often referred to as “ecstasy” or “molly”, is short for 3,4 methylenedioxymethamphetamine, a A typical dose of 80 - 125 mg lasts three to six hours. psychoactive drug derived from safrole oil. MDMA Some people experience nausea at the outset, but produces effects that resemble both stimulants and after about 45 minutes, report feelings of relaxation psychedelics, as well as its signature effect: a feeling and clarity. MDMA also causes dilation of the pupils of connectedness. It impacts brain function primarily and, often, sensitivity to light, as well as possible jaw- releasing the neurotransmitter serotonin, and also clenching, tooth-grinding, muscle tension, faintness, temporarily inhibits its reuptake. MDMA is usually and chills or sweating. taken orally, whether in pressed pill form, powder or crystal; or sometimes snorted. After the drug wears off, the theory from preclinical studies is that brain levels of serotonin (a chemical MDMA was originally synthesized in 1912 by the drug responsible for maintaining mood balance) are company Merck.1 However, its psychoactive effects depleted, which can lead in some cases to sadness, weren’t widely discovered until 1976 when Alexander anxiety, depression and sleep problems.4 If they occur, Shulgin developed a new synthesis method, tested the these symptoms arise in the several days that follow. drug on himself, and shared it with a few friendly Generally, they abate within a week, though frequency psychotherapists.2 Because of the drug’s effects of of use and higher doses can slow or stop this increasing empathy and reducing fear, it started to be process.5 used in psychotherapy practices in the 1970s and early 80s, as well as recreationally.
    [Show full text]
  • MDMA ('Ecstasy'): a Review of Its Harms and Classification Under the Misuse of Drugs Act 1971
    MDMA (‘ecstasy’): A REVIEW OF ITS HARMS AND CLASSIFICATION UNDER THE MISUSE OF DRUGS ACT 1971 Advisory Council on the Misuse of Drugs ACMD Advisory Council on the Misuse of Drugs 3rd Floor (SW), Seacole Building 2 Marsham Street London SW1P 4DF February 2008 Rt Hon Jacqui Smith MP Home Office 2 Marsham Street London SW1P 4DF Dear Home Secretary, The Advisory Council on the Misuse of Drugs (ACMD) recently considered that a review of MDMA (‘ecstasy’) would be timely as there is a much greater body of evidence regarding the harms and misuse of MDMA since the Council last provided its advice to Ministers in 1996. I have pleasure in enclosing the Council’s report. The use of MDMA is undoubtedly harmful. I would therefore like to emphasise that the Council continues to be concerned about the widespread use of MDMA; particularly among young people. Due to its prevalence of use, MDMA is a significant public health issue and we believe that criminal justice measures will only have limited effect. You will wish to note that the Council strongly advises the promulgation of public health messages. It is of vital importance that issues of classification do not detract from messages concerning public health. Forensic evidence shows that MDMA is by far the most commonly seized of the ‘ecstasy-like’ drugs. MDMA is presently generically classified in Class A under the Misuse of Drugs Act with other ‘ecstasy-like’ drugs. The ACMD has not extended this review to other compounds within the generic classification since their use is considerably less than that of MDMA.
    [Show full text]
  • Psychoactive Drugs of Misuse: Rationalising the Irrational
    Comment Psychoactive drugs of misuse: rationalising the irrational Ideally, policy responses to psychoactive drugs of misuse (1920–32) make it unlikely that any industrialised society would take into account the variations in harm that each will criminalise alcohol use. But that still leaves plenty of kind causes to users and the community. In today’s Lancet, room for more effective use of taxation and regulatory David Nutt and colleagues1 show that the UK classification controls to reduce alcohol-related harm. of psychoactive drugs into three categories of harm (A, Populism favours tough policies towards illicit drugs such B, and C) is only modestly correlated with expert ratings as cannabis. Psychoactive drugs (other than alcohol and of the harms caused. They also point out the obvious: the tobacco) remain the last holdout of the most restrictive classification excludes the psychoactive drugs whose use form of regulation—criminal prohibition—despite the causes the greatest harm—ie, alcohol and tobacco.2 enthusiastic embrace of market deregulation almost Science Photo Library Nutt and colleagues asked UK experts in psychiatry, everywhere else. This situation could change if the USA See Health Policy page 1047 pharmacology, and addiction to rate drugs on three major embraced a free market regime for all psychoactive drugs. dimensions of harm: physical health effects, potential But as attractive as this approach may be to libertarians, for dependence, and social harms. The experts showed it would not be good public-health policy. Allowing a free reasonable levels of agreement in their rankings. By market for all currently illicit drugs would add substantially contrast, their ratings were not well correlated with the UK to the harms now caused by alcohol and tobacco.
    [Show full text]
  • Charlie Hughes (A Minor) by His Mother and Litigation Friend Alison Hughes
    IN THE HIGH COURT OF JUSTICE CLAIM NO: CO/620/2020 ADMINISTRATIVE COURT BETWEEN: THE QUEEN (on the application of) Charlie Hughes (a minor) by his mother and litigation friend Alison Hughes Claimant - and - (1) CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST (2) THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Defendants - and - (1) SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE (2) NHS ENGLAND Interested Parties WITNESS STATEMENT OF PROFESSOR DAVID NUTT I, Professor David Nutt of Drug Science UK will say as follows: 1. I am a psychiatrist and professor at Imperial College London. I have prior training in neurology at Guys and St Mary’s hospitals. My doctorate from Oxford University was on the neuropsychopharmacology of seizures. Since then I have worked for almost all my professional life on the effects, both beneficial and harmful, of drugs on the brain and have extensive clinical and research experience in this field. I am a Fellow of the Royal Colleges of Physicians, of Psychiatrists and of the Academy of Medical Sciences of the UK. I was a member of the Adviory Council on the Misuse of Drugs for 10 years and chair of the Council for one. My expertise has been recognised with a number of prestigious appointments including Presidencies of the European Brain Council, the European College of Neuropsychopharmacology, the British Association of Psychopharmacology and the British Neuroscience Association. I have also served on the MRC Neuroscience board. 2. I have conducted scientific research on the brain actions in humans of a wide range of legal and illegal drugs including alcohol, tobacco, heroin, amfetamines, cocaine, GHB, buprenorphine, antidepressants, benzodiazepines, antipsychotics, methadone, LSD, psilocybin, DMT, cannabis, cannabidiol, ketamine, paracetamol, ibuprofen and caffeine.
    [Show full text]
  • A Placebo-Controlled Investigation of Synaesthesia-Like Experiences Under LSD
    2016, Neuropsychologia A placebo-controlled investigation of synaesthesia-like experiences under LSD Devin B. Terhune Department of Experimental Psychology, University of Oxford, Oxford, UK Department of Psychology, Goldsmiths, University of London, London, UK David P. Luke Department of Psychology & Counselling, University of Greenwich, London, UK Mendel Kaelen Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK Mark Bolstridge Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK Amanda Feilding The Beckley Foundation, Beckley Park, Oxford, UK David Nutt Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK Robin Carhart-Harris Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK Jamie Ward Department of Psychology, University of Sussex, Sussex, UK Correspondence: Devin B. Terhune Department of Psychology, Goldsmiths, University of London, London, UK Email: [email protected] Robin Carhart-Harris Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK Email: [email protected] Jamie Ward Department of Psychology, University of Sussex, Sussex, UK Email: [email protected] Investigating LSD-induced synaesthesia 2 Abstract The induction of synaesthesia in non-synaesthetes has the potential to illuminate the mechanisms that contribute to the development of this condition and the shaping of its phenomenology. Previous research suggests that lysergic acid diethylamide (LSD) reliably induces synaesthesia-like experiences in non- synaesthetes. However, these studies suffer from a number of methodological limitations including lack of a placebo control and the absence of rigorous measures used to test established criteria for genuine synaesthesia.
    [Show full text]
  • Using Multi Criteria Decision Analysis to Estimate Relative Drug Risks and Harms
    Using multi criteria decision analysis to estimate relative drug risks and harms Prof. David Nutt FMedSci Edmond J Safra Prof of Neuropsychopharmacology Imperial College London Chair ISCD drugscience.org.uk [email protected] Drugs are controlled because … They are harmful They might be harmful The media wants it? … as do the majority of politicians … and some of the public So getting the best estimate of harms is vital But difficult • Poor data on existing controlled drugs because illegality covert use • And less for new entrants to the field, “legal highs” 4 key issues 1. Relative harms of drugs - and comparisons with alcohol and tobacco 2. Comparative harms –v- other risky activities 1. Proportionality of penalties cf health harms 2. Benefit-harm equation of the law? 5 A short history of what we have done First - the 9 point scale 2000 Runciman report: develop the 9 point harm assessment scale Drugs and the Law: Report of the Independent Inquiry into the Misuse of Drugs Act 1971. Members of Inquiry: Viscountess Runciman (Chairman), A Chesney, R Fortson, J Hamilton PQPM, S Jenkins, A Maynard, L G Murray, DJ Nutt, D O’Connor QPM, G Pearson, I Wardle, B Williams, A Zera. Report published in 2000. 2001-2006 – Home Office ACMD group systematically reviews a range of drugs using this scale Nutt, DJ; King, LA; Saulsbury, W; Blakemore, C [2007] Developing a rational scale for assessing the risks of drugs of potential misuse Lancet 369:1047-1053 PMID: 17382831 The nine point scale Drug harm ranking Nutt et al 2007 Lancet 8 A short history of what we have done First - the 9 point scale Two2000 Runciman problems: report: develop- the 9 point harm assessment scale Drugs and the Law: Report of the Independent Inquiry into the Misuse of Drugs Act 1971.
    [Show full text]
  • David Nutt Getting a Research Fellow Position at the MRC Clinical Pharmacology Unit in Oxford, Where My Enthusiasm for Research Was Encouraged and Supported
    BMJ CONFIDENTIAL What was your best career move? David Nutt Getting a research fellow position at the MRC Clinical Pharmacology Unit in Oxford, where my enthusiasm for research was encouraged and supported. From then on Fights establishment orthodoxy my career flourished. Who is the person you would most like to thank and why? David Grahame-Smith (director of the MRC Clinical Pharmacology Unit in Oxford), who gave me my first opportunity to do research, from which I’ve never looked back. If you were given £1m what would you spend it on? Developing “alcosynth”—my safe alternative to alcohol. It would lead to a massive health gain as people switched DAVID NUTT has a short name but a from alcohol to this; alcohol currently causes over four long title: Edmond J Safra professor of million premature deaths a year worldwide. Some neuropsychopharmacology at Imperial variants of alcosynth would also have antidotes—so College London. He is famous for you could go to a party, get intoxicated, and then rapidly claiming that riding horses is riskier sober up to drive home safely. than taking ecstasy and for losing his job as a government adviser aft er his Where are or were you happiest? public criticism of drug policy. Many With my children and grandchildren on our annual sprang to his defence, and he established summer beach holiday in north Devon. PETER LOCKE the Independent Scientifi c Committee What single unheralded change has made the most on Drugs, now called DrugScience, difference in your field in your lifetime? which he chairs. He supports a The growing limitations on prescribing medicines that are public health approach to drug “off licence” and thus not evidence based.
    [Show full text]
  • Tolerance to Lysergic Acid Diethylamide: Overview, Correlates, and Clinical Implications
    Chapter 79 Tolerance to Lysergic Acid Diethylamide: Overview, Correlates, and Clinical Implications T. Buchborn, G. Grecksch, D.C. Dieterich, V. Höllt Institute of Pharmacology and Toxicology, Otto-von-Guericke University, Magdeburg, Germany Abbreviations TOLERANCE TO LSD IN HUMANS 5-HT2A Serotonin 2A receptor Tolerance to LSD’s Psychedelic Effect im Intramuscular ip Intraperitoneal Tolerance to LSD’s psychedelic effect has been investigated most LSD Lysergic acid diethylamide comprehensively by Isbell et al. They administered LSD to patients MDA Methylenedioxyamphetamine formerly addicted to opioids (n = 4–11) and across multiple pub- lications tested 11 different administration regimens (Table 1, mGlu2/3 Metabotropic glutamate 2/3 receptor Exps 1–11) (e.g., Isbell, Belleville, Fraser, Wikler, & Logan, 1956). LSD’s psychedelic effect is characterized by (visual) illusions INTRODUCTION and pseudo-hallucinations, formal thought disorders, ambiva- Lysergic acid diethylamide (LSD) is a serotonergic hallucinogen lence, and exaltation of affection, as well as distorted perceptions of time, space, and body-self (e.g., Stoll, 1947). Isbell et al. quan- and, as such, an agonist at serotonin 2A (5-HT2A) receptors that induces profound alterations of human consciousness and ste- tified these by means of Abramson et al.’s 47-item questionnaire, reotypic (gross) motor outputs in animals. LSD, internationally, which asked the patients to self-rate their psychophysiological is very popular among recreational drug users (Barratt, Ferris, state (e.g., “Are shapes and colors altered?” “Do you feel as if in & Winstock, 2014), and human research, after a long halt, has a dream?” or “Do you tremble inside?” Abramson et al., 1955, p. recently been resumed (Carhart-Harris et al., 2014; Schmid et al., 34), as well as of a four-level rating system used by a physician 2015) with efforts to reimplement the drug into psychotherapy to externally estimate the severity of the patient’s perceptual dis- (Gasser et al., 2014).
    [Show full text]
  • Press Reporting of Issues Relating to Illicit Drug Use UK Drug Policy
    Press reporting of issues relating to illicit drug use UK Drug Policy Commission submission to the Leveson Inquiry January 2012 UK Drug Policy Commission Kings Place 90 York Way London N1 9AG (t) 020 7812 3790 (e) [email protected] (w) www.ukdpc.org.uk The UK Drug Policy Commission (UKDPC) is an independent body providing objective analysis of evidence related to UK drug policy. It aims to improve political, media and public understanding of drug policy issues and the options for achieving an effective, evidence-led response to the problems caused by illegal drugs. UKDPC is a company limited by guarantee registered in England and Wales No. 5823583 and is a charity registered in England No. 1118203. The UKDPC is grateful to the Esmée Fairbairn Foundation for its support. The UKDPC brings together senior figures from policing, public policy and the media along with leading experts from the drug treatment and medical research fields: John Varley (President) Dame Ruth Runciman (Chair) Professor Baroness Haleh Afshar OBE Tracey Brown Professor Colin Blakemore FRS David Blakey CBE QPM Annette Dale-Perera Baroness Finlay of Llandaff Jeremy Hardie CBE Professor Alan Maynard OBE Vivienne Parry OBE Adam Sampson Professor John Strang UKDPC Chief Executive: Roger Howard 2 1. Introduction Use of illicit drugs is a topic of frequent interest to the UK press and public, and some aspects of the reporting are a cause for concern, with frequent examples of exaggerated and inaccurate coverage. An analysis in 2010 by the Loughborough Communications Research Centre for UKDPC examined in detail the nature of such coverage in the print media 1.
    [Show full text]